Ensign Peak Advisors
ALLO icon

Ensign Peak Advisors’s Allogene Therapeutics ALLO Stock Holding History

Ensign Peak Advisors’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-20,910
Closed -$226K – 1801
2022
Q3 		$226K Buy
20,910
+2,120
+11% +$28.8K ﹤0.01% 1828
2022
Q2 		$214K Hold
18,790
– – ﹤0.01% 1774
2022
Q1 		$171K Hold
18,790
– – ﹤0.01% 1920
2021
Q4 		$280K Buy
+18,790
New +$332K ﹤0.01% 1839

Other funds holding ALLO

TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Ensign Peak Advisors's ALLO Position: Q4 2022 in Review

Ensign Peak Advisors sold out of Allogene Therapeutics (ALLO) in Q4 2022, closing a stake of 20,910 shares — an estimated $226K sold.

Ensign Peak Advisors first reported a position in ALLO in Q4 2021 and held it in 4 quarters. The position peaked at $280K in Q4 2021. 168 funds tracked by Wall St. Rank hold ALLO as of Q4 2022.

  • Ensign Peak Advisors reported no remaining Allogene Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Ensign Peak Advisors sold 20,910 Allogene Therapeutics shares in Q4 2022, an estimated $226K.
  • Ensign Peak Advisors first reported a position in Allogene Therapeutics in Q4 2021 and held it in 4 quarters.
  • Ensign Peak Advisors's Allogene Therapeutics position peaked at $280K in Q4 2021.
  • 168 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q4 2022.

Based on Ensign Peak Advisors's 13F filing for Q4 2022, filed 13 Feb 2023.